Lablytica Life Science AB started in November 2019 when Recipharm’s GLP bioanalysis business was divested to Center for Translational Research AB (CTR). David Pekar has since then been the Site Manager and Chief Scientific Officer at Lablytica. As announced by CTR, David will from November 1 2020 be the CEO of Lablytica.
David Pekar announced the news on his LinkedIn page, writing the following:
”I am are excited to announce that I have taken on the role as CEO of Lablytica Life Science. During my time as Chief Scientific Officer I continued to gain experience in all practical matters of organizing, as well as building and expanding the company.
This would not have been possible without the great people working at Lablytica, as well as the fantastic board of CTR. I thank all of you for your ongoing support and hard work in making Lablytica a success.
I cannot wait to see where this new chapter of my career will take me, and to grow and learn within this role”.
